Developmental milestones were somewhat delayed: the infant sat alone at 10 months, walked at 18 months, and had a limited vocabulary at 18 months. At one year of age, his islet cell antibodies were negative. At three years, the child's diabetes was controlled on 1.5 units of crystalline insulin and 3 units of NPH in the morning, and 1.0 unit of crystalline insulin and 1.5 units of NPH in the evening. His height was 90.0 cm, weight 13.0 kg and head circumference 49.5 cm.

Transient congenital diabetes mellitus seems unlikely since that condition usually resolves within two to three months, with the most prolonged reported case being 18 months [4].

Prior to our case, the youngest known case of juvenile diabetes mellitus was a 60 h infant reported by Greenwood [5]. It is interesting to note that our patient, as well as Greenwood's, was small for gestational age. These two cases and their catch-up growth subsequent to beginning insulin, support the concept of insulin's playing a role in regulating fetal growth [6].

The sparsity of case reports of permanent congenital diabetes mellitus [7, 8, 9], as well as incidence and prevalence studies of juvenile diabetes from various parts of the world, appears to confirm that the lowest prevalence of this condition occurs within the first month of life. In view of the recognized heterogeneity in diabetes mellitus, such observations – although rare – have definite importance in elucidating the aetiology and natural history.

Yours sincerely,

W. H. Hoffman, C. Khoury, H. A. Byrd

References

1. Crossley JR, Upsdell M (1980) The incidence of juvenile diabetes mellitus in New Zealand. *Diabetologia* 18: 29–34
2. Bloom A, Hayes TM, Gamble DR (1975) Register of newly diagnosed diabetic children. *Br Med J* III: 580–583
3. North AF, Gorwitz K, Sultz HA (1977) A secular increase in the incidence of juvenile diabetes mellitus. *J Pediatr* 91: 706–710
4. Hutchison JH, Keay AJ, Kerr MM (1962) Congenital temporary diabetes mellitus. *Br Med J* II: 436–440
5. Greenwood RD, Traisman HS (1971) Permanent diabetes mellitus in a neonate. *J Pediatr* 79: 296–298
6. Dodge JA, Laurence KM (1977) Congenital absence of islets of Langerhans. *Arch Dis Childh* 52: 411–413
7. Guest GM (1949) Diabetes mellitus in early infancy, without dietary restrictions. *Acta Paediatr Scand* 38: 196–208
8. Lewis SR, Mortimer PE (1964) Idiopathic neonatal hyperglycaemia. *Arch Dis Childh* 39: 618–624
9. Greenwood RD, *op. cit.*

Dr. William H. Hoffman
Children's Hospital of Michigan
Wayne State University
Detroit, MI 48201, USA

Diabetologia 19, 488 (1980)

Diabetologia

© by Springer-Verlag 1980

Interpretation of the Glucose Tolerance Test

Dear Sir,

The need for meaningful criteria by which to interpret the glucose tolerance test (GTT) has been described by many experts [1–4]. It is the purpose of this letter to describe a flaw in criteria recently recommended by an international workgroup sponsored by the National Diabetes Data Group (NDDG) of the National Institutes of Health [4]. The plasma glucose concentration recommended as diagnostic of overt diabetes is a 2 h value and at least one point between the fasting and 2 h value exceeding 200 mg/100 ml on more than one occasion. The problem is the requirement that the abnormal GTT apply on more than one occasion. The GTT is expensive, inconvenient, and stressful, and many physicians are reluctant to require a repeat performance. Diagnostic decisions are often made on the basis of a single GTT. But the NDDG has no classification for subjects who fulfill the criteria for a diabetic GTT on only one occasion. The NDDG defines impaired glucose tolerance as a single GTT with a 2 h value between 140 and 200 mg/100 ml and one point between the fasting and 2 h value exceeding 200 mg/100 ml. By leaving a gap between criteria for overt diabetes and impaired glucose tolerance, the NDDG has clearly established a borderline area, although ostensibly rejecting attempts to define borderline diabetes. Subjects exhibiting an overt diabetic GTT on only one occasion exist in this borderline area. They cannot be classified as overt diabetics because the GTT was performed only once, and they cannot be classified as having impaired glucose tolerance because the 2 h value exceeds 200 mg per 100 ml. The tendency among many community physicians will be to interpret the single diabetic GTT as diagnostic of overt diabetes. This tendency is indeed fostered by the NDDG which states the criteria for a diabetic GTT in the summary of their report but omits the phrase "on more than one occasion" [4].

The criteria for interpreting the GTT should be clear. If borderline diabetes is to be ignored, the gap between criteria for overt diabetes and impaired glucose tolerance should be removed. Im-

paired glucose tolerance could be defined as anything less than the criteria for an overt diabetic GTT.

Alternatively, the gap between criteria for an overt diabetic GTT and impaired glucose tolerance might be preserved and defined as the criteria for borderline diabetes. Certainly the majority of patients with noninsulin-dependent diabetes pass through a precursor stage of overt disease. Although the GTT is unreliable in detecting this precursor stage, it might be wise to allow for the possibility that the GTT in combination with other tests, such as glycosylated haemoglobin, could detect borderline diabetes with adequate accuracy [5].

Yours sincerely,

D. Dix and P. Cohen

References

1. Keen H, Jarrett RJ, Alberti KGMM (1980) Diabetes mellitus: a new look at diagnostic criteria. *Diabetologia* 18: 81
2. Keen H, Jarrett RJ, Alberti KGMM (1979) Diabetes mellitus: a new look at diagnostic criteria. *Diabetologia* 16: 283–285
3. Siperstein MD (1975) The glucose tolerance test: a pitfall in the diagnosis of diabetes mellitus. *Adv Intern Med* 20: 297–323
4. National Diabetes Data Group (1979) Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. *Diabetes* 28: 1039
5. Dix D, Cohen P, Kingsley S, Senkbeil J, Sexton K (1979) Glycohemoglobin and glucose tolerance tests compared as indicators of borderline diabetes. *Clin Chem* 25: 877

D. Dix, P. Cohen
Department of Biology and Health Science
University of Hartford
West Hartford, CT 06117, USA